A cloned frog vasoactive intestinal polypeptide pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals

被引:41
|
作者
Alexandre, D
Anouar, Y
Jegou, S
Fournier, A
Vaudry, H [1 ]
机构
[1] Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, CNRS,INSERM,U413, F-76821 Mont St Aignan, France
[2] Univ Quebec, Inst Natl Rech Sci Sante, Pointe Claire, PQ H9R 1G6, Canada
关键词
D O I
10.1210/en.140.3.1285
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three receptor subtypes for the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) have been identified in mammals: the PAC(1) receptor (PAC(1)-R) which is selectively activated by PACAP, and two VPAC receptors (VPAC(1)-R and VPAC(2)-R), which are equally stimulated by PACAP and VIP. The structures of PACAP and VIP have been well conserved during evolution, but little is known about VIP/PACAP receptors in nonmammalian species. An amphibian VTP/PACAP receptor complementary DNA (cDNA) has been cloned and characterized from a frog (Rana ridibunda) pituitary cDNA library. The predicted protein contains seven putative transmembrane domains and exhibits the highest sequence identity (65%) with the human VPAC(1)-R. The cloned cDNA was transiently expressed in LLC-PK1 cells, and its pharmacological profile was determined in comparison with the human VPAC(1)-R. Both PACAP and VIP stimulated cAMP accumulation through the cloned receptor with an EC50 of about 30 nM. In contrast, secretin, at concentrations that stimulate the human VPAC(1)-R, had no effect on cAMP production. RT-PCR analysis revealed the widespread distribution of this frog VIP/PACAP receptor in peripheral tissues. In situ hybridization histochemistry using a complementary RNA probe showed that the receptor gene is highly expressed in several hypothalamic and thalamic nuclei and to a lesser extent, in the pallium and striatum. In the pituitary, the highest messenger RNA levels were detected in the distal lobe. Taken together, these data show that the cloned frog receptor shares several common features with both the VPAC(1)-R and VPAC(2)-R of mammals; the frog receptor exhibits the highest sequence identity with mammalian VPAC(1)-R, but the lack of effect of secretin and the brain distribution of the receptor are reminiscent of the characteristics of the mammalian VPAC(2)-R. The sequence of the frog receptor should thus prove useful to decipher the structure-activity relationships of the VIP/PACAP receptor family.
引用
收藏
页码:1285 / 1293
页数:9
相关论文
共 50 条
  • [31] Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion
    Nogi, H
    Hashimoto, H
    Hagihara, N
    Shimada, S
    Yamamoto, K
    Matsuda, T
    Tohyama, M
    Baba, A
    NEUROSCIENCE LETTERS, 1997, 227 (01) : 37 - 40
  • [32] The human vasoactive intestinal peptide pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): Constitutive activation by mutations at threonine 343
    Gaudin, P
    Couvineau, A
    Rouyer-Fessard, C
    Maoret, JJ
    Laburthe, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 254 (01) : 15 - 20
  • [33] Pituitary adenylate cyclase-activating polypeptide regulates brain-derived neurotrophic factor exon IV expression through the VPAC1 receptor in the amphibian melanotrope cell
    Kidane, Adhanet H.
    Roubos, Eric W.
    Jenks, Bruce G.
    ENDOCRINOLOGY, 2008, 149 (08) : 4177 - 4182
  • [34] Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland
    Mazzocchi, G
    Malendowicz, LK
    Rebuffat, P
    Gottardo, L
    Nussdorfer, GG
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (06): : 2575 - 2580
  • [35] Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors
    Igarashi, H
    Ito, T
    Mantey, SA
    Pradhan, TK
    Hou, W
    Coy, DH
    Jensen, RT
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (01): : 370 - 381
  • [36] Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis
    Zupan, V
    Hill, JM
    Brenneman, DE
    Gozes, I
    Fridkin, M
    Robberecht, P
    Evrard, P
    Gressens, P
    JOURNAL OF NEUROCHEMISTRY, 1998, 70 (05) : 2165 - 2173
  • [37] Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist -: Alanine scanning and molecular modeling of the peptide
    Nicole, P
    Lins, L
    Rouyer-Fessard, C
    Drouot, C
    Fulcrand, P
    Thomas, A
    Couvineau, A
    Martinez, J
    Brasseur, R
    Laburthe, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) : 24003 - 24012
  • [38] Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland
    Vertongen, P
    Delhase, M
    Rajas, F
    Trouillas, J
    HooghePeters, E
    Svoboda, M
    Robberecht, P
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1996, 16 (03) : 239 - 248
  • [39] Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity
    Ganea, D
    Delgado, M
    CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2002, 13 (03) : 229 - 237
  • [40] Characterization and messenger ribonucleic acid distribution of a cloned pituitary adenylate cyclase-activating polypeptide type I receptor in the frog Xenopus laevis brain
    Hu, ZT
    Lelievre, V
    Chao, A
    Zhou, XR
    Waschek, JA
    ENDOCRINOLOGY, 2000, 141 (02) : 657 - 665